Spina Bifida

01Pathophysiology

Neural tube closure is one of the earliest and most critical events in human embryogenesis. The process begins around day 21 and is completed by day 28 of gestation. The neural plate folds inward and fuses in a bidirectional, zipper-like fashion from the center toward both ends. The anterior (rostral) neuropore closes around day 25, while the posterior (caudal) neuropore closes around day 28. Spina bifida results from a failure of this caudal closure.

The underlying biochemistry centers on folate metabolism. Folic acid serves as a one-carbon donor in the synthesis of purines and thymidylate, which are essential building blocks for DNA replication. It also participates in methylation reactions that regulate gene expression during neural tube closure. When folate is deficient, the rapidly dividing cells of the neural plate cannot replicate their DNA efficiently, and the caudal neuropore fails to fuse. This explains why folate supplementation before conception is the single most effective preventive measure.

Valproic acid and carbamazepine are teratogenic because they interfere with folate metabolism through inhibition of folate absorption and increased folate catabolism. This is why women on these medications require higher-dose folate supplementation and ideally a switch to a less teratogenic antiepileptic before conception.

The neurological deficits in spina bifida correlate directly with the level of the vertebral defect. Because the spinal cord and nerve roots are exposed or herniated through the bony defect, all motor and sensory function below that level may be compromised. A lesion at L3 to L5 causes flaccid paralysis of the lower limbs, loss of sensation, and dysfunction of bowel and bladder (both are innervated by sacral nerve roots S2 to S4). Higher lesions produce more extensive deficits.

A key associated anomaly is the Chiari II malformation (also called Arnold-Chiari malformation), which is present in nearly all cases of myelomeningocele. During fetal development, cerebrospinal fluid (CSF) leaks out through the open spinal defect, reducing intracranial pressure and causing the posterior fossa to be underdeveloped. The cerebellar tonsils and vermis herniate downward through the foramen magnum, obstructing CSF flow and leading to obstructive hydrocephalus. This is why infants with myelomeningocele are monitored closely for a rapidly increasing head circumference.

02Classification and Clinical Manifestation

Spina bifida occulta is the mildest and most common form. It is often discovered incidentally on a lumbosacral X-ray obtained for another reason. The overlying skin markers (tuft of hair, dimple, hemangioma) are tested frequently as clues in vignettes. Despite its benign nature, occulta can occasionally cause a tethered spinal cord, presenting later in childhood or adolescence with progressive gait abnormality, back pain, scoliosis, and bladder dysfunction.

Myelomeningocele is the most clinically significant and most commonly tested form. A key teaching point: if you see a newborn with a lumbosacral cystic mass AND neurological deficits, the answer is myelomeningocele, not meningocele. Meningocele preserves neurological function because the neural tissue is not herniated.

03Diagnostic Workup

The first clue in most exam vignettes is an elevated MSAFP on the routine second-trimester "quad screen." MSAFP is the best initial screening test for open neural tube defects. The AFP is produced by the fetal liver and yolk sac. When the neural tube is open, AFP leaks freely from exposed neural tissue into the amniotic fluid and then crosses into the maternal circulation. This is why closed defects (spina bifida occulta, skin-covered meningocele) do not elevate MSAFP, and why understanding the distinction between "open" and "closed" defects is critical.

When MSAFP is elevated, the next step is a targeted prenatal ultrasound. The ultrasonographer looks for intracranial signs of Chiari II malformation (lemon sign, banana sign, ventriculomegaly) and directly visualizes the spinal defect. Ultrasound is now highly sensitive for detecting myelomeningocele when performed at experienced centers.

If ultrasound findings are equivocal or need confirmation, amniocentesis is performed. The key finding is elevated amniotic fluid AFP combined with a positive acetylcholinesterase (AChE). AChE is released from exposed neural tissue and is more discriminating than AFP alone because AFP can be elevated for other reasons (abdominal wall defects such as gastroschisis and omphalocele, fetal demise, twin gestation). Positive AChE in the setting of elevated AFP is highly confirmatory for an open neural tube defect.

After birth, MRI of the spine and brain is the gold standard. It precisely defines the level and extent of the defect, the presence and degree of Chiari II malformation, hydrocephalus, and any associated findings such as tethered cord or syringomyelia. A head ultrasound is performed early to monitor ventricular size, and urological evaluation (renal ultrasound and VCUG) is initiated to assess for neurogenic bladder and vesicoureteral reflux, which if untreated can lead to recurrent urinary tract infections, hydronephrosis, and renal damage.

04Management and Treatment

Prevention is the highest-yield management concept. All women of childbearing age should take folic acid 0.4 mg daily regardless of whether they are planning a pregnancy, because neural tube closure occurs by day 28, often before pregnancy is recognized. Women at high risk (prior pregnancy affected by a neural tube defect, maternal use of valproic acid or carbamazepine, pregestational diabetes) require a ten-fold higher dose of 4 mg daily, starting at least one month before conception and continued through the first 12 weeks of gestation.

Prenatal repair was validated by the Management of Myelomeningocele Study (MOMS trial), which demonstrated that fetal surgery performed between 19 and 25 weeks of gestation reduced the incidence of hydrocephalus requiring shunting (from 82% to 40%) and improved motor function at 30 months compared to postnatal repair. However, prenatal repair carries risks including preterm premature rupture of membranes and preterm delivery, and it is performed only at experienced fetal surgery centers with strict inclusion criteria.

At birth, the immediate priorities are wound protection and infection prevention. The defect must be kept moist with sterile saline-soaked nonadherent gauze. The infant is positioned to keep pressure off the sac. Broad-spectrum antibiotics are initiated to prevent meningitis. Definitive surgical closure is performed within 24 to 72 hours. Delay beyond this window significantly increases the risk of central nervous system infection and progressive neurological deterioration.

Hydrocephalus develops in the majority of myelomeningocele patients due to Chiari II malformation. Clinical signs include a bulging anterior fontanelle, rapidly increasing head circumference, sunsetting eyes, irritability, and poor feeding. The standard treatment is a VP shunt. Families are counseled on recognizing signs of shunt malfunction (headache, vomiting, lethargy, bulging fontanelle), which is a neurosurgical emergency.

Neurogenic bladder is managed with clean intermittent catheterization, typically performed every 3 to 4 hours. The goal is to prevent urinary stasis, reduce the risk of urinary tract infections, preserve renal function, and achieve social continence. Anticholinergic medications such as oxybutynin may be added to reduce detrusor hyperactivity. Regular urodynamic studies and renal ultrasound are part of long-term surveillance.

One often-overlooked point: patients with spina bifida and repeated surgical exposures have a high incidence of latex allergy (due to repeated mucosal and wound exposure to latex-containing equipment). All patients with myelomeningocele should be maintained in a latex-free environment from birth.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common way students lose points on spina bifida questions is by confusing the prenatal screening pathway. When a vignette presents an elevated MSAFP, many students jump directly to amniocentesis. However, the correct next step after an elevated MSAFP is a targeted ultrasound, not amniocentesis. Ultrasound is noninvasive, readily available, and can often confirm the diagnosis. Amniocentesis is reserved for cases where the ultrasound is inconclusive.

Another frequent trap involves distinguishing meningocele from myelomeningocele. Both present as a back mass, but the vignette will include neurological deficits (paralysis, absent reflexes, bladder dysfunction) only in myelomeningocele. If the child has a back mass but normal neurological function, the answer is meningocele. If there are deficits, it is myelomeningocele.

Students also commonly forget that spina bifida occulta does not elevate MSAFP because the defect is closed (covered by intact skin). If a vignette describes an incidental finding of a tuft of hair or dimple over the lumbosacral spine in an otherwise normal child, the diagnosis is spina bifida occulta, and the MSAFP would be normal.

The folic acid dosing distinction is tested repeatedly: 0.4 mg for the general population versus 4 mg for high-risk women. Getting the dose wrong (or the timing wrong) is a common error. Supplementation must begin before conception because the neural tube has already closed by the time most women realize they are pregnant.

Finally, always think about Chiari II malformation and hydrocephalus when you see myelomeningocele. These are nearly inseparable associations. If a vignette describes a neonate with a repaired myelomeningocele who then develops irritability, vomiting, and a bulging fontanelle, the diagnosis is hydrocephalus (likely from shunt malfunction or progressive Chiari II obstruction), and the next step is imaging followed by neurosurgical intervention.

The core competency being tested across all spina bifida questions is the ability to link embryology to clinical presentation, correctly sequence the prenatal workup, and recognize the downstream complications that require lifelong multidisciplinary management.